Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2013

01-01-2013 | Original paper

Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer

Authors: Yen Ching Chen, Yi Ling Huang, Elizabeth A. Platz, John F. Alderete, Lu Zheng, Jennifer R. Rider, Peter Kraft, Edward Giovannucci, Siobhan Sutcliffe

Published in: Cancer Causes & Control | Issue 1/2013

Login to get access

Abstract

Purpose

In previous studies, we observed a positive association between Trichomonas vaginalis serostatus and risk of prostate cancer, particularly aggressive cancer, which we hypothesized might be due to T. vaginalis-mediated intraprostatic inflammation and cell damage. To explore this hypothesis further, we investigated effect modification by Toll-like receptor 4 (TLR4) variation on this association. We hypothesized that TLR4 variation might serve a marker of the anti-trichomonad immune response because T. vaginalis has been shown to elicit inflammation through this receptor.

Methods

We previously genotyped the non-synonymous TLR4 single nucleotide polymorphism (SNP), rs4986790, and determined T. vaginalis serostatus for 690 incident prostate cancer cases and 692 controls in a nested case–control study within the Health Professionals Follow-up Study.

Results

A non-significant suggestion of effect modification was observed by rs4986790 carrier status on the association between T. vaginalis serostatus and prostate cancer risk (p interaction = 0.07). While no association was observed among men homozygous wildtype for this SNP (odds ratio (OR) = 1.23, 95 % confidence interval (CI): 0.86–1.77), a positive association was observed among variant carriers (OR = 4.16, 95 % CI: 1.32–13.1).

Conclusions

Although not statistically significant, TLR4 variation appeared to influence the association between T. vaginalis serostatus and prostate cancer risk consistent with the hypothesis that inflammation plays a role in this association. Larger studies will be necessary to explore this possible effect modification further.
Appendix
Available only for authorised users
Literature
1.
Holmes KK, Sparling PF, Stamm WE et al (eds) (2008) Sexually transmitted diseases, 4th edn. McGraw-Hill Medical, New York
2.
Wynder EL, Mabuchi K, Whitmore WF Jr (1971) Epidemiology of cancer of the prostate. Cancer 28(2):344–360PubMedCrossRef
3.
Gardner WA Jr, Culberson DE, Bennett BD (1986) Trichomonas vaginalis in the prostate gland. Arch Pathol Lab Med 110(5):430–432PubMed
4.
Smith CJ, Gardner WA Jr (1987) Inflammation-proliferation: possible relationships in the prostate. In: Coffey DS, Bruchovsky N, Gardner WA, Resnick MI, Karr JP (eds) Current concepts and approaches to the study of prostate cancer. Alan R. Liss, Inc., New York, pp 317–25
5.
Sutcliffe S, Giovannucci E, Alderete JF et al (2006) Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(5):939–945PubMedCrossRef
6.
Stark JR, Judson G, Alderete JF et al (2009) Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians’ Health Study. J Natl Cancer Inst 101(20):1406–1411PubMedCrossRef
7.
Sutcliffe S, Alderete JF, Till C et al (2009) Trichomonosis and subsequent risk of prostate cancer in the prostate cancer prevention trial. Int J Cancer 124(9):2082–2087PubMedCrossRef
8.
Zariffard MR, Harwani S, Novak RM et al (2004) Trichomonas vaginalis infection activates cells through toll-like receptor 4. Clin Immunol 111(1):103–107PubMedCrossRef
9.
Chang JH, Kim SK, Choi IH et al (2006) Apoptosis of macrophages induced by Trichomonas vaginalis through the phosphorylation of p38 mitogen-activated protein kinase that locates at downstream of mitochondria-dependent caspase activation. Int J Biochem Cell Biol 38(4):638–647PubMedCrossRef
10.
Schroder NW, Schumann RR (2005) Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5(3):156–164PubMed
11.
den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ (2010) Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 209(2):314–320CrossRef
12.
Chen YC, Giovannucci E, Lazarus R et al (2005) Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 65(24):11771–11778PubMedCrossRef
13.
Wang A, Wang CC, Alderete JF (1987) Trichomonas vaginalis phenotypic variation occurs only among trichomonads infected with the double-stranded RNA virus. J Exp Med 166(1):142–150PubMedCrossRef
14.
Khoshnan A, Alderete JF (1995) Characterization of double-stranded RNA satellites associated with the Trichomonas vaginalis virus. J Virol 69(11):6892–6897PubMed
15.
Lehker MW, Alderete JF (1992) Iron regulates growth of Trichomonas vaginalis and the expression of immunogenic trichomonad proteins. Mol Microbiol 6(1):123–132PubMedCrossRef
16.
Alderete JF (1999) Iron modulates phenotypic variation and phosphorylation of P270 in double-stranded RNA virus-infected Trichomonas vaginalis. Infect Immun 67(8):4298–4302PubMed
17.
Lehker MW, Arroyo R, Alderete JF (1991) The regulation by iron of the synthesis of adhesins and cytoadherence levels in the protozoan Trichomonas vaginalis. J Exp Med 174(2):311–318PubMedCrossRef
18.
Alderete JF, Provenzano D, Lehker MW (1995) Iron mediates Trichomonas vaginalis resistance to complement lysis. Microb Pathog 19(2):93–103PubMedCrossRef
19.
Garcia AF, Benchimol M, Alderete JF (2005) Trichomonas vaginalis polyamine metabolism is linked to host cell adherence and cytotoxicity. Infect Immun 73(5):2602–2610PubMedCrossRef
20.
Provenzano D, Alderete JF (1995) Analysis of human immunoglobulin-degrading cysteine proteinases of Trichomonas vaginalis. Infect Immun 63(9):3388–3395PubMed
21.
Lama A, Kucknoor A, Mundodi V, Alderete JF (2009) Glyceraldehyde-3-phosphate dehydrogenase is a surface-associated, fibronectin-binding protein of Trichomonas vaginalis. Infect Immun 77(7):2703–2711PubMedCrossRef
22.
Alderete JF, Newton E, Dennis C, Neale KA (1991) The vagina of women infected with Trichomonas vaginalis has numerous proteinases and antibody to trichomonad proteinases. Genitourin Med 67(6):469–474PubMed
23.
Kucknoor AS, Mundodi V, Alderete JF (2007) The proteins secreted by Trichomonas vaginalis and vaginal epithelial cell response to secreted and episomally expressed AP65. Cell Microbiol 9(11):2586–2597PubMedCrossRef
24.
Kucknoor AS, Mundodi V, Alderete JF (2005) Adherence to human vaginal epithelial cells signals for increased expression of Trichomonas vaginalis genes. Infect Immun 73(10):6472–6478PubMedCrossRef
25.
Zheng SL, Augustsson-Balter K, Chang B et al (2004) Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the cancer prostate in Sweden study. Cancer Res 64(8):2918–2922PubMedCrossRef
26.
Cheng I, Plummer SJ, Casey G, Witte JS (2007) Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16(2):352–355PubMedCrossRef
27.
Wang MH, Helzlsouer KJ, Smith MW et al (2009) Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 69(8):874–885PubMedCrossRef
28.
Stark JR, Wiklund F, Gronberg H et al (2009) Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 18(6):1859–1863PubMedCrossRef
29.
Lindstrom S, Hunter DJ, Gronberg H et al (2010) Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. Cancer Epidemiol Biomarkers Prev 19(3):873–876PubMedCrossRef
30.
Shui IM, Stark JR, Penney KL et al (2012) Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate 72(2):209–216
Metadata
Title
Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer
Authors
Yen Ching Chen
Yi Ling Huang
Elizabeth A. Platz
John F. Alderete
Lu Zheng
Jennifer R. Rider
Peter Kraft
Edward Giovannucci
Siobhan Sutcliffe
Publication date
01-01-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 1/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0103-y

Other articles of this Issue 1/2013

Cancer Causes & Control 1/2013 Go to the issue

Original paper

Nutrition in early life and risk of childhood leukemia: a case–control study in Greece

Original paper

The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans

Original paper

Red and processed meat intake and risk of esophageal adenocarcinoma: a meta-analysis of observational studies

Original paper

Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium

Original Paper

Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium

Letter to the editor

Formaldehyde and leukemia: missing evidence!
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits